Palatin Technologies Inc. (PTN)

[PepsiMan]

Vyleesi™ (bremelanotide) MC4r Agonist

Hypoactive Sexual Desire Disorder


1. Pre-Clinical (CHECK).
2. Phase 1 (CHECK).
3. Phase 2 (CHECK).
4. Phase 3 (CHECK).
5. NDA Submission (CHECK).
6. FDA APPROVAL (PENDING).

___________________________________________


PL-8177 MC1r Agonist

Inflammatory Bowel Diseases

1. Pre-Clinical (CHECK).
2. Phase 1 (CHECK).

___________________________________________


PL-8331 MC1/5r Agonist

Anti-inflammatory Ocular Indications


1. Pre-Clinical Stage (currently in Pre-Clinical Stage).


____________________________________________



MC4r Agonist Peptide & Small Molecules

Rare Genetic Metabolic and Obesity Disorders


1. Pre-Clinical (currently in Pre-Clinical Stage).


____________________________________________


PL-3994 NPR-A

Cardiovascular Diseases

1. Pre-Clinical (CHECK).
2. Phase 1 (CHECK).
3. Phase 2 (Entering Phase 2).


_____________________________________________


PL-5028 NPR-A/C Agonist

Cardiac Hypertrophy and Fibrosis


1. Pre-Clinical (currently in Pre-Clinical Stage).

______________________________________________




$PTN is a dynamic company with many studies in the works.




PEPSI